VistaGen Therapeutics has partnered with the US Baylor College of Medicine (Baylor) to carry out an interventional clinical trial of AV-101 as a potential treatment for suicidal veterans.

The randomised, placebo-controlled, double-blind cross-over trial is expected to enrol altogether 12 healthy veterans from either Operation Enduring Freedom, Operation Iraqi Freedom or Operation New Dawn.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the trial, the subjects will receive single doses of AV-101 at 720mg and 1,440mg, as well as placebo, over a period of three weeks.

The trial aims to define a dose-response relationship between AV-101 and relevant biomarkers associated with N-methyl-D-aspartate (NMDA) function and others possibly related to suicidality, as well as safety and tolerability.

“The results of this initial study in healthy volunteer Veterans could lead to a Phase ll study involving AV-101 and Veterans who are battling suicidal ideation or behaviours.”

The trial’s principal investigator Dr Marijn Lijffijt said: “The suicide rate is two times higher in Veterans than in citizens of equivalent age and gender. A priority for suicide prevention is to come up with novel treatment targets for safe and rapidly acting interventions to impact acute suicidality, which is not adequately addressed with current treatments.

“This study is the first step in working to revolutionise the way that we treat suicidal ideation and behaviours. Our expectation is to complete the dosing by the end of September 2018, with top-line results from the study expected by the year end.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The results of this initial study in healthy volunteer Veterans could lead to a Phase ll study involving AV-101 and Veterans who are battling suicidal ideation or behaviours.”

AV-101 is currently being studied in two separate Phase lll clinical studies for the treatment of major depressive disorder.